Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/ijms23073715
Keywords
pituitary adenylate cyclase activating polypeptide; heart failure; ischemic; non-ischemic cardiomyopathy; NT-proBNP; cytokines
Funding
- Hungarian Scientific Research Fund [K119759, K129190, K135457, GINOP-2.3.2-15-2016-00050]
- Hungarian Academy of Sciences [MTA-TKI-14016, 2021 Health Sub-programme]
- Ministry for Innovation and Technology in Hungary [KA-2019-30]
- European Union [739593, NVKP_16-1-2016-0017]
- National Research, Development and Innovation Fund of Hungary
- National Research, Development and Innovation Office (NKFIH) of Hungary [FK134751]
- Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences [uNKP-19-4]
- New National Excellence Program of the Ministry for Innovation and Technology
- National Brain Research Program [2017-1.2.1-NKP-2017-00002, NAP-2]
- Lorand Eotvos Research Network
Ask authors/readers for more resources
This study aimed to investigate the presence of PACAP-38 in heart failure (HF) patients and its correlation with HF predictors. The results showed that plasma PACAP-38 immunoreactivity was higher in acute HF patients, while lower in chronic HF patients. In addition, a positive correlation between plasma PACAP-38 and NT-proBNP levels was observed in acute HF, but a negative correlation in chronic HF. The levels of cytokines IL-1 beta, IL-2, IL-4 were lower in chronic HF, and IL-10 was higher in acute HF. PACAP-38 levels in myocardial tissues were lower in all end-stage HF patients. The study suggests that PACAP-38 may be a potential prognostic biomarker in HF.
Pituitary adenylate cyclase activating polypeptide-38 (PACAP-38) is a multifunctional neuropeptide, which may play a role in cardioprotection. However, little is known about the presence of PACAP-38 in heart failure (HF) patients. The aim of our study was to measure the alterations of PACAP-38 like immunoreactivity (LI) in acute (n = 13) and chronic HF (n = 33) and to examine potential correlations between PACAP-38 and HF predictors (cytokines, NT-proBNP). Tissue PACAP-38 LI and PAC1 receptor levels were also investigated in heart tissue samples of patients with HF. Significantly higher plasma PACAP-38 LI was detected in patients with acute HF, while in chronic HF patients, a lower level of immunoreactivity was observed compared to healthy controls (n = 13). Strong negative correlation was identified between plasma PACAP-38 and NT-proBNP levels in chronic HF, as opposed to the positive connection seen in the acute HF group. Plasma IL-1 beta, IL-2 and IL-4 levels were significantly lower in chronic HF, and IL-10 was significantly higher in patients with acute HF. PACAP-38 levels of myocardial tissues were lower in all end-stage HF patients and lower PAC1 receptor levels were detected in the primary dilated cardiomyopathy group compared to the controls. We conclude that PACAP-38 and PAC1 expression correlates with some biomarkers of acute and chronic HF; therefore, further studies are necessary to explore whether PACAP could be a suitable prognostic biomarker in HF patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available